Evolus Inc (NASDAQ:EOLS)
| 11.69 Delayed Data As of May 24 |  +0.04 / +0.34%Today’s Change | 5.06 Today|||52-Week Range 14.34 | +79.57% Year-to-Date |
Latest EOLS News | Press Releases
| Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know May 23 / Zacks.com - Paid Partner Content | Has Evolus (EOLS) Outpaced Other Medical Stocks This Year? May 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 11.65 |
| Today’s open | 11.81 |
| Day’s range | 11.65 - 11.87 |
| Volume | 21,818 |
| Average volume (3 months) | 525,948 |
| Market cap | $679.9M |
Data as of 4:00pm ET, 05/24/2022
Growth & Valuation
| Earnings growth (last year) | +80.54% |
| Earnings growth (this year) | +7.48% |
| Earnings growth (next 5 years) | +16.00% |
| Revenue growth (last year) | +76.29% |
| P/E ratio | NM |
| Price/Sales | 3.25 |
| Price/Book | 8.23 |
Competitors
Data as of 4:00pm ET, 05/24/2022
Financials
| Next reporting date | August 4, 2022 |
| EPS forecast (this quarter) | -$0.26 |
| Annual revenue (last year) | $99.7M |
| Annual profit (last year) | -$46.8M |
| Net profit margin | -46.96% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Newport Beach, California |
Forecasts
